Stay updated with breaking news from Reducer System. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Enhances Johnson & Johnson’s Ability to Transform the Treatment Landscape for Cardiovascular Disease and Continue to Improve Patient Outcomes Extends Johnson & Johnson MedTech’s Position in...
Johnson & Johnson to acquire Shockwave Medical for $335.00/share in cash, bolstering its cardiovascular intervention portfolio. The acquisition, expected to close by mid-2024, signifies Johnson & Johnson's strategic focus on innovation and market expansion.
Drug major Johnson & Johnson (JNJ) announced Friday its agreement to acquire Shockwave Medical, Inc. (SWAV) for $335.00 per share in cash. The enterprise value of the deal is around $13.
The proposed new payment structure by the CMS would help Shockwave's business.
Neovasc’s Innovative Reducer System will target the estimated $5 billion refractory angina market